Fraud office looks at GSK

Share this article:

GlaxoSmithKline is under investigation by the United Kingdom's Serious Fraud Office. The drugmaker announced the investigation Tuesday and said in a statement that it is “committed to operating its business to the highest ethical standards,” and will cooperate with the government investigation.

The New York Times reported that neither GSK nor the UK agency would discuss just what is being investigated, but noted the string of allegations of misconduct by authorities in China, the most recent one being accusations that GSK employee Mark Reilly implemented a bribery scheme in China.

The company has also been accused of misconduct in Iraq, Jordan and Lebanon, among other locations.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.